- Ustekinumab-aekn (Selarsdi) is approved as interchangeable with the reference biologic ustekinumab (Stelara) for various indications, including psoriasis and arthritis. 2. It is also approved for Crohn's disease and ulcerative colitis in both adult and pediatric patients. 3. The biosimilar's safety profile aligns with the reference biologic, with risks for serious infections and adverse events. 4. Alvotech and Teva Pharmaceuticals are strategic partners in commercializing multiple biosimilars. 5. Other biosimilars under FDA review include proposed biosimilars to golimumab and aflibercept.
Source: Teva Pharmaceuticals
